FUSION Biomed is a boutique executive search firm, partnering with early stage life science and healthtech companies.
We find the people and the money - you bring the great idea
We put our arms around early stage life science and healthtech companies and enable them to grow and achieve their ambitions.
FUSION Biomed is a specialist search and investment partner for boards, early-stage CEOs and founding scientists looking to commercialise innovative science with ambitions to grow world-class companies and transform patient lives.
We connect our clients quickly with the right skills at the right time whether via virtual teams or by hiring high demand impactful leaders. We work closely with the investment community, bringing the best funding fit for our clients business as it grows.
By finding the right people and money at the right time, we de-risk and enable companies to increase market share and accelerate shareholder value.
CEO, emerging pharmaceutical company - A virtual pharmaceutical company set up to exploit the potential of a single API which has clear platform potential across all sites where epithelial cells are present. These include, dermatology, GI, UTI, respiratory and endothelial targets. The company has focused on a single initial target therapeutic which is orphan designated and ready for Phase III confirmatory trials. The initial target market is the wound space.
The CEO role will suit an entrepreneurial, dynamic leader who values great science and has the capabilities to drive the company to success by setting and implementing strategy, working with key stakeholders, to lead the achievement of company vision.
Chief Business Officer, Atelerix - Atelerix is a young company, spun out from Newcastle University and incorporated in June 2017. It was formed to commercialise the invention of Prof. Che Connon of the storage and transport of mammalian cells and tissues at “hypothermic” (lower than 37°C) temperatures. The company is exploiting this with customers in two different market sectors – the use of cells as research tools for drug discovery and development, and the use of cells as therapies in their own right.
We are seeking an experienced, strategic yet hands-on CBO who will develop a strong working relationship with the CEO to ensure the company achieves its strategic goals and fulfils its mission. A pivotal role for the continued growth of Atelerix, this is a highly strategic position for a dynamic leader wanting to impact the success of the business whilst building shareholder value.
CEO, CytoSeek - CytoSeek Limited is an early stage University of Bristol spin-out company based on the research of Dr Adam Perriman. The company is commercialising a novel cell membrane modification technology, which has the potential to significantly enhance the efficacy of cell therapies.
We are seeking a proven leader to shape and lead the development and growth of the company.
Confidential search for Chief Financial Officer - We are searching for an experienced CFO to work alongside the CEO to continue to build the company and prepare for exit.
Chair, Peome - Preome is an early stage venture, based at Stevenage Bioscience Catalyst, developing a suite of scalable technology platforms to improve clinical success rates. The AI-based platform has a number of cross—sector applications.
To enable Preome’s ambitions to be met, an experienced, strong, independent Chair is required to support the CEO to define and achieve the company’s aims and to determine and drive the necessary strategy to success
VP, Business Development, ROW, ADC Biotechnology - ADC Biotechnology are a leading Custom Development & Manufacturing Organisation (CDMO) specialising in the rapidly growing Antibody Drug Conjugate (ADC) based anti-cancer drugs sector, offering R&D services, production development and GMP manufacturing of ADCs.
We are seeking a dynamic business development leader, with international experience, to impact on the continued success and growth of this world class CDMO.
For more information or to discuss any role further please contact us.